<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027351</url>
  </required_header>
  <id_info>
    <org_study_id>V72P6E1</org_study_id>
    <secondary_id>EUDRACT 2009-013054-33</secondary_id>
    <nct_id>NCT01027351</nct_id>
  </id_info>
  <brief_title>Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine</brief_title>
  <official_title>A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naïve Children and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Novartis Vaccine as Infants in Study V72P6</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The proposed study V72P6E1 is an Extension Study of V72P6 (NCT00381615). The objectives of
      this extension study will be to explore antibody persistence at approximately 40 months of
      age and to evaluate the safety, tolerability and immunogenicity of booster doses of rMenB±OMV
      NZ administered to subjects at approximately 40 months of age. Antibody persistence will be
      subsequently measured at 18-20 months after these booster doses when the subjects are 60
      months of age. Two groups of naïve subjects, aged approximately 40 and 60 months, will be
      recruited in the study to serve as a baseline comparator for assessing antibody persistence
      at these ages. These subjects will receive a two-dose catch-up regimen with rMenB+OMV NZ.
      Subjects who are enrolled at 40 months of age are offered DTaP/IPV and MMR vaccinations, if
      they have not already received these vaccines prior to enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Persistence of Geometric Mean Antibody Titers in Children (Who Previously Received 4 Doses of Men B Vaccine), at 40 Months of Age.</measure>
    <time_frame>28 months after last vaccination; Baseline for Naïve</time_frame>
    <description>Persistence of geometric mean titers (GMTs) against N.meningitidis B strains in children (at 40 months of age) who had previously received four doses of either rMenB or rMen+OMV NZ vaccines in parent study, are compared with the GMTs in vaccine-naïve children.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects (Who Previously Received 4 Doses of Men B Vaccine) With Persisting Human Complement Serum Bactericidal Antibody Titers ≥ 1:4 and ≥1:8 at 40 Months of Age.</measure>
    <time_frame>28 months after last vaccination; baseline for naïve</time_frame>
    <description>The percentages of subjects with persisting human serum bactericidal antibodies (hSBA) titers ≥ 1:4 and ≥ 1:8, against N.meningitidis B strains at 40 months of age; who had previously received four doses of either rMenB or rMen+OMV NZ vaccines in parent study are reported.
The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events After a Receiving One or Two Booster Doses of rMen B or rMenB+OMV NZ Vaccine at 40 Months of Age.</measure>
    <time_frame>Day 1-7 after booster vaccination</time_frame>
    <description>The safety and tolerability of one or two booster doses of rMen B or rMenB+OMV NZ vaccine administered at 40 months of age in children who had previously received one or four doses of the same vaccine as infants in parent study is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of Geometric Mean Antibody Titers in Children (Who Previously Received One Dose of Men B Vaccine), at 40 Months of Age.</measure>
    <time_frame>28 months after vaccination; Baseline for Naïve</time_frame>
    <description>Persisting GMTs against N.meningitidis B strains in children (at 40 months of age) who had previously received one dose of either rMenB or rMen+OMV NZ vaccines in parent study, are compared with the GMTs in vaccine-naïve children.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (Who Had Previously Received One Dose of Men B Vaccine) With Persisting Serum Bactericidal Antibody Titers ≥ 1:4 and ≥1:8, at 40 Months of Age.</measure>
    <time_frame>28 months after vaccination; baseline for naïve</time_frame>
    <description>The percentages of subjects with persisting hSBA titers ≥ 1:4 and ≥1:8, against N.meningitidis B strains at 40 months of age; who had previously received one dose of either rMenB or rMen+OMV NZ vaccines in parent study are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers in Children (Who Previously Received 4 Doses of Men B Vaccine), After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age.</measure>
    <time_frame>1 month post- booster/ dose 1 for Naïve</time_frame>
    <description>The GMTs against N.meningitidis B strains in children (who had previously received four doses MenB vaccine in parent study) after a single booster dose of rMenB or rMenB+OMV NZ vaccine given at 40 months of age, are compared with the antibody titers following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (Who Previously Received 4 Doses of Men B Vaccine) With Serum Bactericidal Antibody Titers ≥ 1:4 and ≥1:8 After Receiving a Booster Dose of Either rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age.</measure>
    <time_frame>1 month post- booster/ dose 1 for Naïve</time_frame>
    <description>The percentages of subjects (who had previously received four doses MenB vaccine in parent study) with hSBA titers ≥ 1:4 and ≥ 1:8, against N.meningitidis B strains after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccines at 40 months of age are compared with hSBA responses following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects (Who Previously Received 4 Doses of Men B Vaccine) With 4-fold Increase in Serum Bactericidal Antibody Titers After Receiving a Booster Dose of Either rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age.</measure>
    <time_frame>1 month post - booster/ -dose 1 for Naïve</time_frame>
    <description>The percentages of subjects (who had previously received four doses MenB vaccine in parent study) showing a 4-fold increase in hSBA titers over baseline against N.meningitidis B strains, after receiving a booster dose of either rMenB or rMen+OMV NZ vaccines at 40 months of age are compared with hSBA responses following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects.
Baseline is defined as either the time that the (first) booster dose was given or the time of the first vaccination in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers in Children After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ Vaccine at 40 &amp; 42 Months of Age.</measure>
    <time_frame>1 month post vaccination</time_frame>
    <description>The GMTs against N.meningitidis B strains in children (who had previously received one dose MenB vaccine in parent study) after a two booster doses of either rMenB or rMenB+OMV NZ vaccine given at 40 &amp; 42 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Serum Bactericidal Antibody Titers ≥ 1:4 and ≥ 1:8 After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ Vaccine at 40 &amp; 42 Months of Age.</measure>
    <time_frame>1 month post vaccination</time_frame>
    <description>The percentages of subjects (who had previously received one dose of MenB vaccine in parent study) with hSBA ≥ 1:4 and ≥ 1:8, against N.meningitidis B strains after receiving two booster doses of either rMenB or rMenB+OMV NZ vaccine at 40 &amp; 42 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 4-fold Increase in Antibody Titers After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ Vaccine at 40 &amp; 42 Months of Age.</measure>
    <time_frame>1 month post vaccination</time_frame>
    <description>The percentages of subjects (who had previously received one dose of MenB vaccine in parent study) displaying 4-fold increase in antibody titers over baseline against N.meningitidis B strains, after receiving two booster doses of either rMenB or rMenB+OMV NZ vaccine at 40 &amp; 42 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titers ≥ 1:4 and ≥1:8 Following Two Catch up Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age.</measure>
    <time_frame>1 month post -vaccine dose two</time_frame>
    <description>The percentage of subjects with hSBA ≥ 1:4 and ≥ 1:8 after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40 &amp; 42 months or 60 &amp; 62 months of age are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers in Children After Two Catch up Doses of rMenB+OMV NZ Vaccine Given, Either at 40 or 60 Months of Age.</measure>
    <time_frame>1 month post vaccine dose two</time_frame>
    <description>The geometric mean antibody titers in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40 &amp; 42 months or 60 &amp; 62 months of age are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With a 4-fold Increase in Antibody Titers After Receiving Two Catch up Doses of rMenB+OMV NZ Vaccine, Either at 40 or 60 Months of Age.</measure>
    <time_frame>1 month post vaccine dose 2</time_frame>
    <description>The percentages of subjects with four-fold increase in hSBA titers over baseline against N.meningitidis B one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 &amp; 42 months or 60 &amp; 62 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting Geometric Mean Antibody Titers Against N.Meningitidis B in Children at 60 Months of Age.</measure>
    <time_frame>18-20 months after last Men B vaccine; baseline for naïve_6062</time_frame>
    <description>The persisting GMTs against N.meningitidis B strains in children at 60 months of age who had received one or two booster doses of either rMenB or rMenB+ OMV NZ vaccine or had received two catch-up doses of rMenB+ OMV NZ vaccine at 40 months of age in the present study are compared with GMTs in vaccine-naïve subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Persisting Serum Bactericidal Antibodies ≥1:4 and ≥1:8 in Children at 60 Months of Age.</measure>
    <time_frame>18-20 months after last Men B vaccine; baseline for naïve_6062</time_frame>
    <description>The percentage of subjects with persisting hSBA titers ≥1:4 and ≥1:8 at 60 months of age against N.meningitidis B strains after having received one or two booster doses of either rMenB or rMenB+ OMV NZ vaccine or had received two catch-up doses of rMenB+ OMV NZ vaccine at 40 months of age in the present are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children (Who Had Previously Received 4 Doses of MenB Vaccine in Parent Study) at 40 Months of Age.</measure>
    <time_frame>28 months after last Men B vaccination; Baseline for Naïve_4042 group</time_frame>
    <description>The persisting geometric mean antibody concentrations (GMCs) against vaccine antigen 287-953 in children (at 40 months of age) who had previously received 4 doses of either rMenB or rMen+OMV NZ vaccines in parent study , are compared with the the GMCs in vaccine-naïve children.
GMCs against vaccine antigen 287-953 were measured using enzyme linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children (Who Had Previously Received 1dose of MenB Vaccine in Parent Study) at 40 Months of Age.</measure>
    <time_frame>28 months after last Men B vaccination; baseline for naïve_4042 group</time_frame>
    <description>The persisting GMCs against vaccine antigen 287-953 in children (at 40 months of age) who had previously received 1 dose of either rMenB or rMen+OMV NZ vaccines in parent study , are compared with the the GMCs in vaccine-naïve children.
GMCs against vaccine antigen 287-953 were measure using ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children (Who Had Previously Received 4 Doses of MenB Vaccine) After Receiving One Booster Dose of Either rMenB or rMenB+OMV NZ at 40 Months of Age.</measure>
    <time_frame>1 month post booster; 1 month post dose for naïve_4042 group</time_frame>
    <description>The GMCs against vaccine antigen 287-953 in children (who had previously received four doses MenB vaccine in parent study) after a single booster dose of either rMenB or rMenB+OMV NZ vaccine given at 40 months of age, are compared with the GMCs following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ at 40 &amp; 42 Months of Age.</measure>
    <time_frame>1 month after each booster/ vaccine dose</time_frame>
    <description>The GMCs against vaccine antigen 287-953 in children (who had previously received 1 dose of either rMenB or rMen+OMV NZ vaccines in parent study) , are compared with the GMCs in children who received to catch-up doses of rMenB+OMV NZ at 40 &amp; 42 months .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations Against Vaccine Antigen 287-953 in Children After Two Catch up Doses of rMenB+OMV NZ Vaccine Given Either at 40 or 60 Months of Age.</measure>
    <time_frame>1 month post vaccine dose two</time_frame>
    <description>The GMCs against vaccine antigen 287-953 in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at - 40 &amp; 42 months or 60 &amp; 62 months of age are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persisting Geometric Mean Concentrations Against Vaccine Antigen 287-953 in Children at 60 Months of Age.</measure>
    <time_frame>18-20 months after last Men B vaccine; baseline for naïve_6062</time_frame>
    <description>The persisting GMCs against vaccine antigen 287-953 in children at 60 months of age who had either received one or two booster doses of either rMenB or rMenB+OMV NZ vaccine or had received two catch-up doses of rMenB+OMV NZ vaccine at 40 months of age in the present are compared with GMCs in vaccine-naïve subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After a Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine Either at 40 Months or 60 Months of Age.</measure>
    <time_frame>Day 1-7 after any vaccination</time_frame>
    <description>The safety and tolerability of two catch-up doses of rMenB+OMV NZ vaccine when administered either at 40 &amp; 42 months or 60 &amp; 62 months of age in children is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>5rMenB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5rMenB+OMV NZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3rMenB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine without OMV (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3rMenB+OMV NZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naive_4042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 40 and 42 months of age in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naive_6062</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 60 and 62 months of age in the present study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (group B) multicomponent recombinant adsorbed vaccine.</intervention_name>
    <description>Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.</description>
    <arm_group_label>5rMenB+OMV NZ</arm_group_label>
    <arm_group_label>3rMenB+OMV NZ</arm_group_label>
    <arm_group_label>Naive_4042</arm_group_label>
    <arm_group_label>Naive_6062</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)</intervention_name>
    <description>Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).</description>
    <arm_group_label>5rMenB</arm_group_label>
    <arm_group_label>3rMenB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 40 to 44-months-old children, who participated and completed the study V72P6
             (NCT00381615; follow-on subjects)

          -  Healthy 40 to 44-months or 60 to 62-months-old children (naïve subjects)

        Exclusion Criteria:

          -  Previous ascertained or suspected disease caused by N. meningitidis

          -  History of severe allergic reaction after previous vaccinations or hypersensitivity to
             any vaccine component

          -  Any serious chronic or progressive disease

          -  Known or suspected impairment/alteration of the immune system

          -  Receipt of, or intent to immunize with another vaccine, within 30 days prior and after
             vaccination with the investigational vaccines (within 14 days for licensed flu
             vaccines)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Months</minimum_age>
    <maximum_age>62 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <results_first_submitted>December 18, 2013</results_first_submitted>
  <results_first_submitted_qc>April 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2014</results_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Pre-school</keyword>
  <keyword>Meningococcal disease</keyword>
  <keyword>Prevention</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 1 center in the United Kingdom.</recruitment_details>
      <pre_assignment_details>All subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>5rMenB</title>
          <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
        </group>
        <group group_id="P2">
          <title>5rMenB+OMV NZ</title>
          <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
        </group>
        <group group_id="P3">
          <title>3rMenB</title>
          <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
        </group>
        <group group_id="P4">
          <title>3rMenB+OMV NZ</title>
          <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
        </group>
        <group group_id="P5">
          <title>Naive_4042</title>
          <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
        </group>
        <group group_id="P6">
          <title>Naive_6062</title>
          <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis was done on the all enrolled set.</population>
      <group_list>
        <group group_id="B1">
          <title>5rMenB</title>
          <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
        </group>
        <group group_id="B2">
          <title>5rMenB+OMV NZ</title>
          <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
        </group>
        <group group_id="B3">
          <title>3rMenB</title>
          <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
        </group>
        <group group_id="B4">
          <title>3rMenB+OMV NZ</title>
          <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
        </group>
        <group group_id="B5">
          <title>Naive_4042</title>
          <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
        </group>
        <group group_id="B6">
          <title>Naive_6062</title>
          <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="43"/>
            <count group_id="B6" value="50"/>
            <count group_id="B7" value="163"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="1.5"/>
                    <measurement group_id="B2" value="41.8" spread="1.4"/>
                    <measurement group_id="B3" value="41.4" spread="1.5"/>
                    <measurement group_id="B4" value="40.4" spread="0.7"/>
                    <measurement group_id="B5" value="41.8" spread="1.7"/>
                    <measurement group_id="B6" value="61.3" spread="0.9"/>
                    <measurement group_id="B7" value="47.6" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Persistence of Geometric Mean Antibody Titers in Children (Who Previously Received 4 Doses of Men B Vaccine), at 40 Months of Age.</title>
        <description>Persistence of geometric mean titers (GMTs) against N.meningitidis B strains in children (at 40 months of age) who had previously received four doses of either rMenB or rMen+OMV NZ vaccines in parent study, are compared with the GMTs in vaccine-naïve children.</description>
        <time_frame>28 months after last vaccination; Baseline for Naïve</time_frame>
        <population>The analysis was done on the Modified- Intended to treat (MITT), 40 months of age, antibody persistence population.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of Geometric Mean Antibody Titers in Children (Who Previously Received 4 Doses of Men B Vaccine), at 40 Months of Age.</title>
          <description>Persistence of geometric mean titers (GMTs) against N.meningitidis B strains in children (at 40 months of age) who had previously received four doses of either rMenB or rMen+OMV NZ vaccines in parent study, are compared with the GMTs in vaccine-naïve children.</description>
          <population>The analysis was done on the Modified- Intended to treat (MITT), 40 months of age, antibody persistence population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H 44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" lower_limit="2.33" upper_limit="4.52"/>
                    <measurement group_id="O2" value="5.34" lower_limit="3.47" upper_limit="8.23"/>
                    <measurement group_id="O3" value="4.25" lower_limit="3.22" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (N=28, 17, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" lower_limit="2.33" upper_limit="11"/>
                    <measurement group_id="O2" value="28" lower_limit="10" upper_limit="77"/>
                    <measurement group_id="O3" value="1.11" lower_limit="0.9" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.79" upper_limit="1.51"/>
                    <measurement group_id="O2" value="2.77" lower_limit="1.81" upper_limit="4.23"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (N=28, 15, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.15" lower_limit="5.01" upper_limit="17"/>
                    <measurement group_id="O2" value="5.34" lower_limit="2.35" upper_limit="12"/>
                    <measurement group_id="O3" value="8.75" lower_limit="5.22" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects (Who Previously Received 4 Doses of Men B Vaccine) With Persisting Human Complement Serum Bactericidal Antibody Titers ≥ 1:4 and ≥1:8 at 40 Months of Age.</title>
        <description>The percentages of subjects with persisting human serum bactericidal antibodies (hSBA) titers ≥ 1:4 and ≥ 1:8, against N.meningitidis B strains at 40 months of age; who had previously received four doses of either rMenB or rMen+OMV NZ vaccines in parent study are reported.
The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).</description>
        <time_frame>28 months after last vaccination; baseline for naïve</time_frame>
        <population>The analysis was done on the MITT , 40 months of age, antibody persistence population.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (Who Previously Received 4 Doses of Men B Vaccine) With Persisting Human Complement Serum Bactericidal Antibody Titers ≥ 1:4 and ≥1:8 at 40 Months of Age.</title>
          <description>The percentages of subjects with persisting human serum bactericidal antibodies (hSBA) titers ≥ 1:4 and ≥ 1:8, against N.meningitidis B strains at 40 months of age; who had previously received four doses of either rMenB or rMen+OMV NZ vaccines in parent study are reported.
The serum bactericidal antibodies directed against serogroup B meningococci, are measured by human complement Serum Bactericidal Assay (hSBA).</description>
          <population>The analysis was done on the MITT , 40 months of age, antibody persistence population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA ≥1:4 (H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="26" upper_limit="64"/>
                    <measurement group_id="O2" value="65" lower_limit="38" upper_limit="86"/>
                    <measurement group_id="O3" value="63" lower_limit="46" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:4 (5/99 strain; N=28, 17, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="24" upper_limit="63"/>
                    <measurement group_id="O2" value="76" lower_limit="50" upper_limit="93"/>
                    <measurement group_id="O3" value="3" lower_limit="0.063" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:4 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.087" upper_limit="18"/>
                    <measurement group_id="O2" value="41" lower_limit="18" upper_limit="67"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:4 (M10713 strain; N=28, 15, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="48" upper_limit="84"/>
                    <measurement group_id="O2" value="67" lower_limit="38" upper_limit="88"/>
                    <measurement group_id="O3" value="68" lower_limit="51" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O2" value="35" lower_limit="14" upper_limit="62"/>
                    <measurement group_id="O3" value="30" lower_limit="17" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:8 (5/99 strain; N=28, 17, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="24" upper_limit="63"/>
                    <measurement group_id="O2" value="76" lower_limit="50" upper_limit="93"/>
                    <measurement group_id="O3" value="3" lower_limit="0.063" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:8 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="24" lower_limit="7" upper_limit="50"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:8 (M10713 strain; N=28, 15, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="41" upper_limit="78"/>
                    <measurement group_id="O2" value="40" lower_limit="16" upper_limit="68"/>
                    <measurement group_id="O3" value="45" lower_limit="29" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events After a Receiving One or Two Booster Doses of rMen B or rMenB+OMV NZ Vaccine at 40 Months of Age.</title>
        <description>The safety and tolerability of one or two booster doses of rMen B or rMenB+OMV NZ vaccine administered at 40 months of age in children who had previously received one or four doses of the same vaccine as infants in parent study is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.</description>
        <time_frame>Day 1-7 after booster vaccination</time_frame>
        <population>Analysis was done on the safety population i.e all subjects who received at least one Men B vaccination and provided post-baseline safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O4">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Adverse Events After a Receiving One or Two Booster Doses of rMen B or rMenB+OMV NZ Vaccine at 40 Months of Age.</title>
          <description>The safety and tolerability of one or two booster doses of rMen B or rMenB+OMV NZ vaccine administered at 40 months of age in children who had previously received one or four doses of the same vaccine as infants in parent study is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.</description>
          <population>Analysis was done on the safety population i.e all subjects who received at least one Men B vaccination and provided post-baseline safety data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic preventive medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic treatment medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of Geometric Mean Antibody Titers in Children (Who Previously Received One Dose of Men B Vaccine), at 40 Months of Age.</title>
        <description>Persisting GMTs against N.meningitidis B strains in children (at 40 months of age) who had previously received one dose of either rMenB or rMen+OMV NZ vaccines in parent study, are compared with the GMTs in vaccine-naïve children.</description>
        <time_frame>28 months after vaccination; Baseline for Naïve</time_frame>
        <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
        <group_list>
          <group group_id="O1">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) in the parent study, were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) in the parent study, were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of Geometric Mean Antibody Titers in Children (Who Previously Received One Dose of Men B Vaccine), at 40 Months of Age.</title>
          <description>Persisting GMTs against N.meningitidis B strains in children (at 40 months of age) who had previously received one dose of either rMenB or rMen+OMV NZ vaccines in parent study, are compared with the GMTs in vaccine-naïve children.</description>
          <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" lower_limit="1.8" upper_limit="7.15"/>
                    <measurement group_id="O2" value="3.47" lower_limit="1.39" upper_limit="8.64"/>
                    <measurement group_id="O3" value="4.25" lower_limit="3.22" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.57" lower_limit="3.88" upper_limit="24"/>
                    <measurement group_id="O2" value="1" lower_limit="0.3" upper_limit="3.3"/>
                    <measurement group_id="O3" value="1.11" lower_limit="0.9" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.96" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1" lower_limit="0.72" upper_limit="1.38"/>
                    <measurement group_id="O3" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (N=13, 8, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" lower_limit="1.49" upper_limit="7.11"/>
                    <measurement group_id="O2" value="3" lower_limit="1.11" upper_limit="8.11"/>
                    <measurement group_id="O3" value="8.75" lower_limit="5.22" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (Who Had Previously Received One Dose of Men B Vaccine) With Persisting Serum Bactericidal Antibody Titers ≥ 1:4 and ≥1:8, at 40 Months of Age.</title>
        <description>The percentages of subjects with persisting hSBA titers ≥ 1:4 and ≥1:8, against N.meningitidis B strains at 40 months of age; who had previously received one dose of either rMenB or rMen+OMV NZ vaccines in parent study are reported.</description>
        <time_frame>28 months after vaccination; baseline for naïve</time_frame>
        <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
        <group_list>
          <group group_id="O1">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (Who Had Previously Received One Dose of Men B Vaccine) With Persisting Serum Bactericidal Antibody Titers ≥ 1:4 and ≥1:8, at 40 Months of Age.</title>
          <description>The percentages of subjects with persisting hSBA titers ≥ 1:4 and ≥1:8, against N.meningitidis B strains at 40 months of age; who had previously received one dose of either rMenB or rMen+OMV NZ vaccines in parent study are reported.</description>
          <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA ≥1:4 (H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="29" upper_limit="82"/>
                    <measurement group_id="O2" value="38" lower_limit="9" upper_limit="76"/>
                    <measurement group_id="O3" value="63" lower_limit="46" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:4 (5/99 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="29" upper_limit="82"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="37"/>
                    <measurement group_id="O3" value="3" lower_limit="0.063" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:4 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="0" upper_limit="34"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="37"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:4 (M10713 strain; N=13, 8, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="25" upper_limit="81"/>
                    <measurement group_id="O2" value="25" lower_limit="3" upper_limit="65"/>
                    <measurement group_id="O3" value="68" lower_limit="51" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="0" upper_limit="34"/>
                    <measurement group_id="O2" value="13" lower_limit="0" upper_limit="53"/>
                    <measurement group_id="O3" value="30" lower_limit="17" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:8 (5/99 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="18" upper_limit="71"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="37"/>
                    <measurement group_id="O3" value="3" lower_limit="0.063" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:8 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="23"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="37"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:8 (M10713 strain; N=13, 8, 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="2" upper_limit="45"/>
                    <measurement group_id="O2" value="13" lower_limit="0" upper_limit="53"/>
                    <measurement group_id="O3" value="45" lower_limit="29" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers in Children (Who Previously Received 4 Doses of Men B Vaccine), After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age.</title>
        <description>The GMTs against N.meningitidis B strains in children (who had previously received four doses MenB vaccine in parent study) after a single booster dose of rMenB or rMenB+OMV NZ vaccine given at 40 months of age, are compared with the antibody titers following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects.</description>
        <time_frame>1 month post- booster/ dose 1 for Naïve</time_frame>
        <population>The analysis was done on the MITT population, booster response.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers in Children (Who Previously Received 4 Doses of Men B Vaccine), After Receiving a Booster Dose of rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age.</title>
          <description>The GMTs against N.meningitidis B strains in children (who had previously received four doses MenB vaccine in parent study) after a single booster dose of rMenB or rMenB+OMV NZ vaccine given at 40 months of age, are compared with the antibody titers following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects.</description>
          <population>The analysis was done on the MITT population, booster response.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="67" upper_limit="145"/>
                    <measurement group_id="O2" value="89" lower_limit="56" upper_limit="141"/>
                    <measurement group_id="O3" value="12" lower_limit="7.96" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (N=28, 18, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="778" lower_limit="448" upper_limit="1349"/>
                    <measurement group_id="O2" value="1708" lower_limit="859" upper_limit="3396"/>
                    <measurement group_id="O3" value="22" lower_limit="12" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" lower_limit="0.95" upper_limit="2.85"/>
                    <measurement group_id="O2" value="47" lower_limit="24" upper_limit="91"/>
                    <measurement group_id="O3" value="7.73" lower_limit="4.62" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (N=28, 18, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="24" upper_limit="59"/>
                    <measurement group_id="O2" value="39" lower_limit="22" upper_limit="67"/>
                    <measurement group_id="O3" value="11" lower_limit="6.7" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (Who Previously Received 4 Doses of Men B Vaccine) With Serum Bactericidal Antibody Titers ≥ 1:4 and ≥1:8 After Receiving a Booster Dose of Either rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age.</title>
        <description>The percentages of subjects (who had previously received four doses MenB vaccine in parent study) with hSBA titers ≥ 1:4 and ≥ 1:8, against N.meningitidis B strains after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccines at 40 months of age are compared with hSBA responses following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects .</description>
        <time_frame>1 month post- booster/ dose 1 for Naïve</time_frame>
        <population>The analysis was done on the MITT population, booster response.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (Who Previously Received 4 Doses of Men B Vaccine) With Serum Bactericidal Antibody Titers ≥ 1:4 and ≥1:8 After Receiving a Booster Dose of Either rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age.</title>
          <description>The percentages of subjects (who had previously received four doses MenB vaccine in parent study) with hSBA titers ≥ 1:4 and ≥ 1:8, against N.meningitidis B strains after receiving a single booster dose of either rMenB or rMen+OMV NZ vaccines at 40 months of age are compared with hSBA responses following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects .</description>
          <population>The analysis was done on the MITT population, booster response.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA ≥1:4 (H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O3" value="89" lower_limit="75" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:4 (5/99 strain; N=28, 18, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="81" upper_limit="100"/>
                    <measurement group_id="O3" value="76" lower_limit="60" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:4 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="4" upper_limit="33"/>
                    <measurement group_id="O2" value="89" lower_limit="67" upper_limit="99"/>
                    <measurement group_id="O3" value="66" lower_limit="49" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:4 (M10713 strain; N=28, 18, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="73" upper_limit="100"/>
                    <measurement group_id="O3" value="76" lower_limit="60" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 ( H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="82" upper_limit="100"/>
                    <measurement group_id="O3" value="63" lower_limit="46" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:8 (5/99 strain; N=28, 18, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="81" upper_limit="100"/>
                    <measurement group_id="O3" value="71" lower_limit="54" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:8 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="2" upper_limit="28"/>
                    <measurement group_id="O2" value="89" lower_limit="67" upper_limit="99"/>
                    <measurement group_id="O3" value="58" lower_limit="41" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA≥1:8 (M10713 strain; N=28, 18, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="72" upper_limit="98"/>
                    <measurement group_id="O2" value="94" lower_limit="73" upper_limit="100"/>
                    <measurement group_id="O3" value="61" lower_limit="43" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects (Who Previously Received 4 Doses of Men B Vaccine) With 4-fold Increase in Serum Bactericidal Antibody Titers After Receiving a Booster Dose of Either rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age.</title>
        <description>The percentages of subjects (who had previously received four doses MenB vaccine in parent study) showing a 4-fold increase in hSBA titers over baseline against N.meningitidis B strains, after receiving a booster dose of either rMenB or rMen+OMV NZ vaccines at 40 months of age are compared with hSBA responses following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects.
Baseline is defined as either the time that the (first) booster dose was given or the time of the first vaccination in this study.</description>
        <time_frame>1 month post - booster/ -dose 1 for Naïve</time_frame>
        <population>The analysis was done on the MITT population, booster response.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (Who Previously Received 4 Doses of Men B Vaccine) With 4-fold Increase in Serum Bactericidal Antibody Titers After Receiving a Booster Dose of Either rMenB or rMenB+OMV NZ Vaccine at 40 Months of Age.</title>
          <description>The percentages of subjects (who had previously received four doses MenB vaccine in parent study) showing a 4-fold increase in hSBA titers over baseline against N.meningitidis B strains, after receiving a booster dose of either rMenB or rMen+OMV NZ vaccines at 40 months of age are compared with hSBA responses following one catch-up dose of rMenB+OMV NZ vaccine given at 40 months in vaccine-naive subjects.
Baseline is defined as either the time that the (first) booster dose was given or the time of the first vaccination in this study.</description>
          <population>The analysis was done on the MITT population, booster response.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="72" upper_limit="98"/>
                    <measurement group_id="O2" value="94" lower_limit="71" upper_limit="100"/>
                    <measurement group_id="O3" value="41" lower_limit="25" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (N=27, 16, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="87" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="70" upper_limit="100"/>
                    <measurement group_id="O3" value="68" lower_limit="50" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="2" upper_limit="28"/>
                    <measurement group_id="O2" value="82" lower_limit="57" upper_limit="96"/>
                    <measurement group_id="O3" value="57" lower_limit="39" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (N=27, 15, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="22" upper_limit="61"/>
                    <measurement group_id="O2" value="67" lower_limit="38" upper_limit="88"/>
                    <measurement group_id="O3" value="14" lower_limit="5" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers in Children After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ Vaccine at 40 &amp; 42 Months of Age.</title>
        <description>The GMTs against N.meningitidis B strains in children (who had previously received one dose MenB vaccine in parent study) after a two booster doses of either rMenB or rMenB+OMV NZ vaccine given at 40 &amp; 42 months of age.</description>
        <time_frame>1 month post vaccination</time_frame>
        <population>The analysis was done on the MITT population, booster response.</population>
        <group_list>
          <group group_id="O1">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers in Children After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ Vaccine at 40 &amp; 42 Months of Age.</title>
          <description>The GMTs against N.meningitidis B strains in children (who had previously received one dose MenB vaccine in parent study) after a two booster doses of either rMenB or rMenB+OMV NZ vaccine given at 40 &amp; 42 months of age.</description>
          <population>The analysis was done on the MITT population, booster response.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain (dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="48" upper_limit="185"/>
                    <measurement group_id="O2" value="76" lower_limit="30" upper_limit="190"/>
                    <measurement group_id="O3" value="12" lower_limit="7.96" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 strain (dose 2; N=13, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" lower_limit="81" upper_limit="198"/>
                    <measurement group_id="O2" value="145" lower_limit="82" upper_limit="255"/>
                    <measurement group_id="O3" value="88" lower_limit="66" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2379" lower_limit="1164" upper_limit="4859"/>
                    <measurement group_id="O2" value="509" lower_limit="192" upper_limit="1348"/>
                    <measurement group_id="O3" value="22" lower_limit="12" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (dose 2; N=13, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5240" lower_limit="3082" upper_limit="8911"/>
                    <measurement group_id="O2" value="2413" lower_limit="1226" upper_limit="4747"/>
                    <measurement group_id="O3" value="1019" lower_limit="762" upper_limit="1362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain (dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="0.86" upper_limit="3.48"/>
                    <measurement group_id="O2" value="148" lower_limit="57" upper_limit="384"/>
                    <measurement group_id="O3" value="7.73" lower_limit="4.62" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain (dose 2; N=13, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" lower_limit="0.89" upper_limit="3.88"/>
                    <measurement group_id="O2" value="65" lower_limit="25" upper_limit="165"/>
                    <measurement group_id="O3" value="47" lower_limit="31" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="18" upper_limit="68"/>
                    <measurement group_id="O2" value="30" lower_limit="12" upper_limit="74"/>
                    <measurement group_id="O3" value="11" lower_limit="6.7" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (dose 2; N=12, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="9.25" upper_limit="47"/>
                    <measurement group_id="O2" value="36" lower_limit="13" upper_limit="98"/>
                    <measurement group_id="O3" value="33" lower_limit="22" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Serum Bactericidal Antibody Titers ≥ 1:4 and ≥ 1:8 After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ Vaccine at 40 &amp; 42 Months of Age.</title>
        <description>The percentages of subjects (who had previously received one dose of MenB vaccine in parent study) with hSBA ≥ 1:4 and ≥ 1:8, against N.meningitidis B strains after receiving two booster doses of either rMenB or rMenB+OMV NZ vaccine at 40 &amp; 42 months of age.</description>
        <time_frame>1 month post vaccination</time_frame>
        <population>The analysis was done on the MITT population, booster response.</population>
        <group_list>
          <group group_id="O1">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Serum Bactericidal Antibody Titers ≥ 1:4 and ≥ 1:8 After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ Vaccine at 40 &amp; 42 Months of Age.</title>
          <description>The percentages of subjects (who had previously received one dose of MenB vaccine in parent study) with hSBA ≥ 1:4 and ≥ 1:8, against N.meningitidis B strains after receiving two booster doses of either rMenB or rMenB+OMV NZ vaccine at 40 &amp; 42 months of age.</description>
          <population>The analysis was done on the MITT population, booster response.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain (≥1:4 - dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O3" value="89" lower_limit="75" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 strain (≥1:4 - dose 2; N=13, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 strain (≥1:8 - dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O3" value="63" lower_limit="46" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 strain (≥1:8 - dose 2; N=13, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (≥1:4 - dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O3" value="76" lower_limit="60" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (≥1:4 - dose 2; N=13, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (≥1:8 - dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O3" value="71" lower_limit="54" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (≥1:8 - dose 2; N=13, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain (≥1:4 - dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="2" upper_limit="45"/>
                    <measurement group_id="O2" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O3" value="66" lower_limit="49" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain (≥1:4 - dose 2; N=13, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="2" upper_limit="45"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="94" lower_limit="81" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain (≥1:8 - dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="2" upper_limit="45"/>
                    <measurement group_id="O2" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O3" value="58" lower_limit="41" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain (≥1:8 - dose 2; N=13, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="2" upper_limit="45"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="94" lower_limit="81" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (≥1:4 - dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="86" lower_limit="42" upper_limit="100"/>
                    <measurement group_id="O3" value="76" lower_limit="60" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (≥1:4 - dose 2; N=12, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="52" upper_limit="98"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="89" lower_limit="74" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (≥1:8 - dose 1; N=13, 7, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="55" upper_limit="98"/>
                    <measurement group_id="O2" value="86" lower_limit="42" upper_limit="100"/>
                    <measurement group_id="O3" value="61" lower_limit="43" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (≥1:8 - dose 2; N=12, 8, 36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="43" upper_limit="95"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="86" lower_limit="71" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 4-fold Increase in Antibody Titers After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ Vaccine at 40 &amp; 42 Months of Age.</title>
        <description>The percentages of subjects (who had previously received one dose of MenB vaccine in parent study) displaying 4-fold increase in antibody titers over baseline against N.meningitidis B strains, after receiving two booster doses of either rMenB or rMenB+OMV NZ vaccine at 40 &amp; 42 months of age.</description>
        <time_frame>1 month post vaccination</time_frame>
        <population>The analysis was done on the MITT population, booster response.</population>
        <group_list>
          <group group_id="O1">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 4-fold Increase in Antibody Titers After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ Vaccine at 40 &amp; 42 Months of Age.</title>
          <description>The percentages of subjects (who had previously received one dose of MenB vaccine in parent study) displaying 4-fold increase in antibody titers over baseline against N.meningitidis B strains, after receiving two booster doses of either rMenB or rMenB+OMV NZ vaccine at 40 &amp; 42 months of age.</description>
          <population>The analysis was done on the MITT population, booster response.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain (dose 1; N=13, 7, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="86" lower_limit="42" upper_limit="100"/>
                    <measurement group_id="O3" value="41" lower_limit="25" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (dose 1; N=13, 7, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O3" value="68" lower_limit="50" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain (dose 1; N=13, 7, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="2" upper_limit="45"/>
                    <measurement group_id="O2" value="100" lower_limit="59" upper_limit="100"/>
                    <measurement group_id="O3" value="57" lower_limit="39" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (dose 1; N=12, 7, 37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="28" upper_limit="85"/>
                    <measurement group_id="O2" value="57" lower_limit="18" upper_limit="90"/>
                    <measurement group_id="O3" value="14" lower_limit="5" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76 strain (dose 2; N=13, 8, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="88" lower_limit="47" upper_limit="100"/>
                    <measurement group_id="O3" value="97" lower_limit="85" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (dose 2; N=13, 8, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="90" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain (dose 2; N=13, 8, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="2" upper_limit="45"/>
                    <measurement group_id="O2" value="100" lower_limit="63" upper_limit="100"/>
                    <measurement group_id="O3" value="94" lower_limit="80" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (dose 2; N=11, 8, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="31" upper_limit="89"/>
                    <measurement group_id="O2" value="75" lower_limit="35" upper_limit="97"/>
                    <measurement group_id="O3" value="53" lower_limit="35" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titers ≥ 1:4 and ≥1:8 Following Two Catch up Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age.</title>
        <description>The percentage of subjects with hSBA ≥ 1:4 and ≥ 1:8 after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40 &amp; 42 months or 60 &amp; 62 months of age are reported.</description>
        <time_frame>1 month post -vaccine dose two</time_frame>
        <population>The analysis was done on the MITT population, 2-dose catch-up regimen.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>Naive_6062</title>
            <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA Titers ≥ 1:4 and ≥1:8 Following Two Catch up Doses of rMenB+OMV NZ Vaccine Given One Month Apart, Either at 40 or 60 Months of Age.</title>
          <description>The percentage of subjects with hSBA ≥ 1:4 and ≥ 1:8 after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40 &amp; 42 months or 60 &amp; 62 months of age are reported.</description>
          <population>The analysis was done on the MITT population, 2-dose catch-up regimen.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA ≥1:4 ( H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="93" lower_limit="81" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (H44/76 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="93" lower_limit="81" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:4 (5/99 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (5/99 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:4 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="81" upper_limit="99"/>
                    <measurement group_id="O2" value="100" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="81" upper_limit="99"/>
                    <measurement group_id="O2" value="90" lower_limit="77" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:4 (M10713 strain; N=36, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="74" upper_limit="97"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (M10713 strain; N=36, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="71" upper_limit="95"/>
                    <measurement group_id="O2" value="98" lower_limit="87" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers in Children After Two Catch up Doses of rMenB+OMV NZ Vaccine Given, Either at 40 or 60 Months of Age.</title>
        <description>The geometric mean antibody titers in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40 &amp; 42 months or 60 &amp; 62 months of age are reported.</description>
        <time_frame>1 month post vaccine dose two</time_frame>
        <population>The analysis was done on the MITT population, 2-dose catch-up regimen.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>Naive_6062</title>
            <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers in Children After Two Catch up Doses of rMenB+OMV NZ Vaccine Given, Either at 40 or 60 Months of Age.</title>
          <description>The geometric mean antibody titers in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at 40 &amp; 42 months or 60 &amp; 62 months of age are reported.</description>
          <population>The analysis was done on the MITT population, 2-dose catch-up regimen.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="63" upper_limit="123"/>
                    <measurement group_id="O2" value="34" lower_limit="25" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1019" lower_limit="688" upper_limit="1510"/>
                    <measurement group_id="O2" value="865" lower_limit="601" upper_limit="1244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="32" upper_limit="69"/>
                    <measurement group_id="O2" value="29" lower_limit="20" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (N=36, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="24" upper_limit="47"/>
                    <measurement group_id="O2" value="43" lower_limit="31" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With a 4-fold Increase in Antibody Titers After Receiving Two Catch up Doses of rMenB+OMV NZ Vaccine, Either at 40 or 60 Months of Age.</title>
        <description>The percentages of subjects with four-fold increase in hSBA titers over baseline against N.meningitidis B one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 &amp; 42 months or 60 &amp; 62 months of age.</description>
        <time_frame>1 month post vaccine dose 2</time_frame>
        <population>The analysis was done on the MITT population, 2-dose catch-up regimen.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>Naive_6062</title>
            <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a 4-fold Increase in Antibody Titers After Receiving Two Catch up Doses of rMenB+OMV NZ Vaccine, Either at 40 or 60 Months of Age.</title>
          <description>The percentages of subjects with four-fold increase in hSBA titers over baseline against N.meningitidis B one month after receiving a two catch-up doses of rMenB+OMV NZ vaccine either at 40 &amp; 42 months or 60 &amp; 62 months of age.</description>
          <population>The analysis was done on the MITT population, 2-dose catch-up regimen.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="85" upper_limit="100"/>
                    <measurement group_id="O2" value="71" lower_limit="54" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="91" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="80" upper_limit="99"/>
                    <measurement group_id="O2" value="89" lower_limit="75" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="35" upper_limit="70"/>
                    <measurement group_id="O2" value="21" lower_limit="10" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persisting Geometric Mean Antibody Titers Against N.Meningitidis B in Children at 60 Months of Age.</title>
        <description>The persisting GMTs against N.meningitidis B strains in children at 60 months of age who had received one or two booster doses of either rMenB or rMenB+ OMV NZ vaccine or had received two catch-up doses of rMenB+ OMV NZ vaccine at 40 months of age in the present study are compared with GMTs in vaccine-naïve subjects.</description>
        <time_frame>18-20 months after last Men B vaccine; baseline for naïve_6062</time_frame>
        <population>The analysis was done on the MITT, 60 months of age, antibody persistence population.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O4">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O5">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O6">
            <title>Naive_6062</title>
            <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
          </group>
        </group_list>
        <measure>
          <title>Persisting Geometric Mean Antibody Titers Against N.Meningitidis B in Children at 60 Months of Age.</title>
          <description>The persisting GMTs against N.meningitidis B strains in children at 60 months of age who had received one or two booster doses of either rMenB or rMenB+ OMV NZ vaccine or had received two catch-up doses of rMenB+ OMV NZ vaccine at 40 months of age in the present study are compared with GMTs in vaccine-naïve subjects.</description>
          <population>The analysis was done on the MITT, 60 months of age, antibody persistence population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain (N=24, 16, 13, 5, 28, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" lower_limit="1.75" upper_limit="5.59"/>
                    <measurement group_id="O2" value="4.68" lower_limit="2.3" upper_limit="9.52"/>
                    <measurement group_id="O3" value="18" lower_limit="8.08" upper_limit="39"/>
                    <measurement group_id="O4" value="13" lower_limit="3.52" upper_limit="45"/>
                    <measurement group_id="O5" value="12" lower_limit="6.27" upper_limit="23"/>
                    <measurement group_id="O6" value="2.98" lower_limit="1.86" upper_limit="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (N=23, 16, 13, 5, 28, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="19" upper_limit="99"/>
                    <measurement group_id="O2" value="136" lower_limit="51" upper_limit="365"/>
                    <measurement group_id="O3" value="369" lower_limit="123" upper_limit="1103"/>
                    <measurement group_id="O4" value="210" lower_limit="36" upper_limit="1227"/>
                    <measurement group_id="O5" value="44" lower_limit="29" upper_limit="67"/>
                    <measurement group_id="O6" value="1.14" lower_limit="0.88" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ 98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.8" upper_limit="1.38"/>
                    <measurement group_id="O2" value="4.95" lower_limit="3.54" upper_limit="6.92"/>
                    <measurement group_id="O3" value="1" lower_limit="0.69" upper_limit="1.45"/>
                    <measurement group_id="O4" value="11" lower_limit="5.93" upper_limit="20"/>
                    <measurement group_id="O5" value="2.42" lower_limit="1.59" upper_limit="3.66"/>
                    <measurement group_id="O6" value="1.04" lower_limit="0.96" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 strain (N=22, 16, 12, 5, 27, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7.22" upper_limit="20"/>
                    <measurement group_id="O2" value="10" lower_limit="5.67" upper_limit="19"/>
                    <measurement group_id="O3" value="12" lower_limit="5.85" upper_limit="24"/>
                    <measurement group_id="O4" value="25" lower_limit="8.47" upper_limit="74"/>
                    <measurement group_id="O5" value="8.52" lower_limit="5.09" upper_limit="14"/>
                    <measurement group_id="O6" value="18" lower_limit="12" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Persisting Serum Bactericidal Antibodies ≥1:4 and ≥1:8 in Children at 60 Months of Age.</title>
        <description>The percentage of subjects with persisting hSBA titers ≥1:4 and ≥1:8 at 60 months of age against N.meningitidis B strains after having received one or two booster doses of either rMenB or rMenB+ OMV NZ vaccine or had received two catch-up doses of rMenB+ OMV NZ vaccine at 40 months of age in the present are reported.</description>
        <time_frame>18-20 months after last Men B vaccine; baseline for naïve_6062</time_frame>
        <population>The analysis was done on the MITT, 60 months of age, antibody persistence population.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O4">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O5">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O6">
            <title>Naive_6062</title>
            <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Persisting Serum Bactericidal Antibodies ≥1:4 and ≥1:8 in Children at 60 Months of Age.</title>
          <description>The percentage of subjects with persisting hSBA titers ≥1:4 and ≥1:8 at 60 months of age against N.meningitidis B strains after having received one or two booster doses of either rMenB or rMenB+ OMV NZ vaccine or had received two catch-up doses of rMenB+ OMV NZ vaccine at 40 months of age in the present are reported.</description>
          <population>The analysis was done on the MITT, 60 months of age, antibody persistence population.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA ≥1:4 (H44/76 strain; N=24, 16, 13, 5, 28, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="26" upper_limit="67"/>
                    <measurement group_id="O2" value="44" lower_limit="20" upper_limit="70"/>
                    <measurement group_id="O3" value="85" lower_limit="55" upper_limit="98"/>
                    <measurement group_id="O4" value="80" lower_limit="28" upper_limit="99"/>
                    <measurement group_id="O5" value="71" lower_limit="51" upper_limit="87"/>
                    <measurement group_id="O6" value="33" lower_limit="20" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:4 (5/99 strain; N=23, 16, 13, 5, 28, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="61" upper_limit="95"/>
                    <measurement group_id="O2" value="88" lower_limit="62" upper_limit="98"/>
                    <measurement group_id="O3" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="48" upper_limit="100"/>
                    <measurement group_id="O5" value="100" lower_limit="88" upper_limit="100"/>
                    <measurement group_id="O6" value="2" lower_limit="0.055" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:4 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O2" value="69" lower_limit="41" upper_limit="89"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="25"/>
                    <measurement group_id="O4" value="80" lower_limit="28" upper_limit="99"/>
                    <measurement group_id="O5" value="31" lower_limit="15" upper_limit="51"/>
                    <measurement group_id="O6" value="2" lower_limit="0.055" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:4 (M10713 strain; N=22, 16, 12, 5, 27, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="55" upper_limit="92"/>
                    <measurement group_id="O2" value="88" lower_limit="62" upper_limit="98"/>
                    <measurement group_id="O3" value="92" lower_limit="62" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="48" upper_limit="100"/>
                    <measurement group_id="O5" value="81" lower_limit="62" upper_limit="94"/>
                    <measurement group_id="O6" value="83" lower_limit="69" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (H44/76 strain; N=24, 16, 13, 5, 28, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="10" upper_limit="47"/>
                    <measurement group_id="O2" value="31" lower_limit="11" upper_limit="59"/>
                    <measurement group_id="O3" value="77" lower_limit="46" upper_limit="95"/>
                    <measurement group_id="O4" value="60" lower_limit="15" upper_limit="95"/>
                    <measurement group_id="O5" value="61" lower_limit="41" upper_limit="78"/>
                    <measurement group_id="O6" value="26" lower_limit="14" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (5/99 strain; N=23, 16, 13, 5, 28, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="52" upper_limit="90"/>
                    <measurement group_id="O2" value="88" lower_limit="62" upper_limit="98"/>
                    <measurement group_id="O3" value="100" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="48" upper_limit="100"/>
                    <measurement group_id="O5" value="93" lower_limit="76" upper_limit="99"/>
                    <measurement group_id="O6" value="2" lower_limit="0.055" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (NZ 98/254 strain)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O2" value="31" lower_limit="11" upper_limit="59"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="25"/>
                    <measurement group_id="O4" value="40" lower_limit="5" upper_limit="85"/>
                    <measurement group_id="O5" value="21" lower_limit="8" upper_limit="40"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥1:8 (M10713 strain; N=22, 16, 12, 5, 27, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="36" upper_limit="79"/>
                    <measurement group_id="O2" value="63" lower_limit="35" upper_limit="85"/>
                    <measurement group_id="O3" value="67" lower_limit="35" upper_limit="90"/>
                    <measurement group_id="O4" value="80" lower_limit="28" upper_limit="99"/>
                    <measurement group_id="O5" value="48" lower_limit="29" upper_limit="68"/>
                    <measurement group_id="O6" value="70" lower_limit="54" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persisting Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children (Who Had Previously Received 4 Doses of MenB Vaccine in Parent Study) at 40 Months of Age.</title>
        <description>The persisting geometric mean antibody concentrations (GMCs) against vaccine antigen 287-953 in children (at 40 months of age) who had previously received 4 doses of either rMenB or rMen+OMV NZ vaccines in parent study , are compared with the the GMCs in vaccine-naïve children.
GMCs against vaccine antigen 287-953 were measured using enzyme linked immunosorbent assay (ELISA).</description>
        <time_frame>28 months after last Men B vaccination; Baseline for Naïve_4042 group</time_frame>
        <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Persisting Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children (Who Had Previously Received 4 Doses of MenB Vaccine in Parent Study) at 40 Months of Age.</title>
          <description>The persisting geometric mean antibody concentrations (GMCs) against vaccine antigen 287-953 in children (at 40 months of age) who had previously received 4 doses of either rMenB or rMen+OMV NZ vaccines in parent study , are compared with the the GMCs in vaccine-naïve children.
GMCs against vaccine antigen 287-953 were measured using enzyme linked immunosorbent assay (ELISA).</description>
          <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
          <units>AU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="59" upper_limit="113"/>
                    <measurement group_id="O2" value="62" lower_limit="41" upper_limit="94"/>
                    <measurement group_id="O3" value="23" lower_limit="19" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persisting Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children (Who Had Previously Received 1dose of MenB Vaccine in Parent Study) at 40 Months of Age.</title>
        <description>The persisting GMCs against vaccine antigen 287-953 in children (at 40 months of age) who had previously received 1 dose of either rMenB or rMen+OMV NZ vaccines in parent study , are compared with the the GMCs in vaccine-naïve children.
GMCs against vaccine antigen 287-953 were measure using ELISA.</description>
        <time_frame>28 months after last Men B vaccination; baseline for naïve_4042 group</time_frame>
        <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
        <group_list>
          <group group_id="O1">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Persisting Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children (Who Had Previously Received 1dose of MenB Vaccine in Parent Study) at 40 Months of Age.</title>
          <description>The persisting GMCs against vaccine antigen 287-953 in children (at 40 months of age) who had previously received 1 dose of either rMenB or rMen+OMV NZ vaccines in parent study , are compared with the the GMCs in vaccine-naïve children.
GMCs against vaccine antigen 287-953 were measure using ELISA.</description>
          <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
          <units>AU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="21" upper_limit="49"/>
                    <measurement group_id="O2" value="28" lower_limit="16" upper_limit="50"/>
                    <measurement group_id="O3" value="23" lower_limit="19" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children (Who Had Previously Received 4 Doses of MenB Vaccine) After Receiving One Booster Dose of Either rMenB or rMenB+OMV NZ at 40 Months of Age.</title>
        <description>The GMCs against vaccine antigen 287-953 in children (who had previously received four doses MenB vaccine in parent study) after a single booster dose of either rMenB or rMenB+OMV NZ vaccine given at 40 months of age, are compared with the GMCs following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects.</description>
        <time_frame>1 month post booster; 1 month post dose for naïve_4042 group</time_frame>
        <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children (Who Had Previously Received 4 Doses of MenB Vaccine) After Receiving One Booster Dose of Either rMenB or rMenB+OMV NZ at 40 Months of Age.</title>
          <description>The GMCs against vaccine antigen 287-953 in children (who had previously received four doses MenB vaccine in parent study) after a single booster dose of either rMenB or rMenB+OMV NZ vaccine given at 40 months of age, are compared with the GMCs following one catch-up dose rMenB+OMV NZ vaccine given at 40 months to vaccine-naive subjects.</description>
          <population>The analysis was done on the MITT, 40 months of age, antibody persistence population.</population>
          <units>AU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5592" lower_limit="3900" upper_limit="8017"/>
                    <measurement group_id="O2" value="3934" lower_limit="2540" upper_limit="6093"/>
                    <measurement group_id="O3" value="64" lower_limit="44" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ at 40 &amp; 42 Months of Age.</title>
        <description>The GMCs against vaccine antigen 287-953 in children (who had previously received 1 dose of either rMenB or rMen+OMV NZ vaccines in parent study) , are compared with the GMCs in children who received to catch-up doses of rMenB+OMV NZ at 40 &amp; 42 months .</description>
        <time_frame>1 month after each booster/ vaccine dose</time_frame>
        <population>The analysis was done on the MITT population, booster response.</population>
        <group_list>
          <group group_id="O1">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Concentrations Against Vaccine Antigen 287-953 in Children After Receiving Two Booster Doses of Either rMenB or rMenB+OMV NZ at 40 &amp; 42 Months of Age.</title>
          <description>The GMCs against vaccine antigen 287-953 in children (who had previously received 1 dose of either rMenB or rMen+OMV NZ vaccines in parent study) , are compared with the GMCs in children who received to catch-up doses of rMenB+OMV NZ at 40 &amp; 42 months .</description>
          <population>The analysis was done on the MITT population, booster response.</population>
          <units>AU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>after 1st booster/vaccine dose (N=13, N=7, N=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2100" lower_limit="1100" upper_limit="4007"/>
                    <measurement group_id="O2" value="1764" lower_limit="731" upper_limit="4256"/>
                    <measurement group_id="O3" value="64" lower_limit="44" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after 2nd booster/vaccine dose (N=13, N=8, N=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3790" lower_limit="2265" upper_limit="6342"/>
                    <measurement group_id="O2" value="3660" lower_limit="1899" upper_limit="7055"/>
                    <measurement group_id="O3" value="3464" lower_limit="2782" upper_limit="4313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations Against Vaccine Antigen 287-953 in Children After Two Catch up Doses of rMenB+OMV NZ Vaccine Given Either at 40 or 60 Months of Age.</title>
        <description>The GMCs against vaccine antigen 287-953 in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at - 40 &amp; 42 months or 60 &amp; 62 months of age are reported.</description>
        <time_frame>1 month post vaccine dose two</time_frame>
        <population>The analysis was done on the MITT population, Booster response.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>Naive_6062</title>
            <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations Against Vaccine Antigen 287-953 in Children After Two Catch up Doses of rMenB+OMV NZ Vaccine Given Either at 40 or 60 Months of Age.</title>
          <description>The GMCs against vaccine antigen 287-953 in children after two catch-up doses of rMenB+OMV NZ vaccine when given either at - 40 &amp; 42 months or 60 &amp; 62 months of age are reported.</description>
          <population>The analysis was done on the MITT population, Booster response.</population>
          <units>AU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3464" lower_limit="2672" upper_limit="4489"/>
                    <measurement group_id="O2" value="1744" lower_limit="1372" upper_limit="2218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persisting Geometric Mean Concentrations Against Vaccine Antigen 287-953 in Children at 60 Months of Age.</title>
        <description>The persisting GMCs against vaccine antigen 287-953 in children at 60 months of age who had either received one or two booster doses of either rMenB or rMenB+OMV NZ vaccine or had received two catch-up doses of rMenB+OMV NZ vaccine at 40 months of age in the present are compared with GMCs in vaccine-naïve subjects.</description>
        <time_frame>18-20 months after last Men B vaccine; baseline for naïve_6062</time_frame>
        <population>The analysis was done on the MITT, 60 months of age, antibody persistence population population.</population>
        <group_list>
          <group group_id="O1">
            <title>5rMenB</title>
            <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>5rMenB+OMV NZ</title>
            <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
          </group>
          <group group_id="O3">
            <title>3rMenB</title>
            <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O4">
            <title>3rMenB+OMV NZ</title>
            <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O5">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O6">
            <title>Naive_6062</title>
            <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
          </group>
        </group_list>
        <measure>
          <title>Persisting Geometric Mean Concentrations Against Vaccine Antigen 287-953 in Children at 60 Months of Age.</title>
          <description>The persisting GMCs against vaccine antigen 287-953 in children at 60 months of age who had either received one or two booster doses of either rMenB or rMenB+OMV NZ vaccine or had received two catch-up doses of rMenB+OMV NZ vaccine at 40 months of age in the present are compared with GMCs in vaccine-naïve subjects.</description>
          <population>The analysis was done on the MITT, 60 months of age, antibody persistence population population.</population>
          <units>AU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="670" lower_limit="475" upper_limit="945"/>
                    <measurement group_id="O2" value="320" lower_limit="210" upper_limit="487"/>
                    <measurement group_id="O3" value="280" lower_limit="175" upper_limit="447"/>
                    <measurement group_id="O4" value="250" lower_limit="118" upper_limit="532"/>
                    <measurement group_id="O5" value="121" lower_limit="88" upper_limit="166"/>
                    <measurement group_id="O6" value="25" lower_limit="20" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After a Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine Either at 40 Months or 60 Months of Age.</title>
        <description>The safety and tolerability of two catch-up doses of rMenB+OMV NZ vaccine when administered either at 40 &amp; 42 months or 60 &amp; 62 months of age in children is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.</description>
        <time_frame>Day 1-7 after any vaccination</time_frame>
        <population>Analysis was done on the MITT – Two Dose Catch Up Schedule population.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive_4042</title>
            <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
          </group>
          <group group_id="O2">
            <title>Naive_6062</title>
            <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After a Receiving Two Catch-up Doses of rMenB+OMV NZ Vaccine Either at 40 Months or 60 Months of Age.</title>
          <description>The safety and tolerability of two catch-up doses of rMenB+OMV NZ vaccine when administered either at 40 &amp; 42 months or 60 &amp; 62 months of age in children is assessed in terms of number of subjects with solicited local and systemic reactions following vaccination.</description>
          <population>Analysis was done on the MITT – Two Dose Catch Up Schedule population.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic preventive medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyretic treatment medication used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1-7 after each vaccination for Solicited AEs; Unsolicited AEs were collected throughout the study period.</time_frame>
      <desc>The analyses for the data in this section are from the safety set. Non serious AEs are reported based on MedDRA version 17.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>5rMenB</title>
          <description>Subjects who had received four doses of rMenB vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB vaccine, at 40 months of age in the present study.</description>
        </group>
        <group group_id="E2">
          <title>5rMenB+OMV NZ</title>
          <description>Subjects who had received four doses of rMenB +OMV NZ vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of rMenB +OMV NZ vaccine, at 40 months of age in the present study.</description>
        </group>
        <group group_id="E3">
          <title>3rMenB</title>
          <description>Subjects who had previously received one dose of rMenB vaccine (at 12 months of age) were administered two doses of rMenB vaccine, at 40 and 42 months of age in the present study.</description>
        </group>
        <group group_id="E4">
          <title>3rMenB+OMV NZ</title>
          <description>Subjects who had previously received one dose of rMenB +OMV NZ vaccine (at 12 months of age) were administered two doses of rMenB +OMV NZ vaccine, at 40 and 42 months of age in the present study.</description>
        </group>
        <group group_id="E5">
          <title>Naive_4042</title>
          <description>Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.</description>
        </group>
        <group group_id="E6">
          <title>Naive_6062</title>
          <description>Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>cystic lymphangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="48" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nasopharingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

